Add time:08/19/2019 Source:sciencedirect.com
The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving LENOGRASTIM (cas 135968-09-1) vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization.Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes.5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy.The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim.
We also recommend Trading Suppliers and Manufacturers of LENOGRASTIM (cas 135968-09-1). Pls Click Website Link as below: cas 135968-09-1 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View